Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT3FLT4KDRKITPDGFRAPDGFRBRET
The experimentally established mechanism targets of Sunitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 16/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 7/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 3/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.84 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.84 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.84 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.84 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.84 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 13/20 | 0.84 |
| ▸ | PRKAA2 | P54646 | 12/20 | 0.84 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.84 |
| ▸ | EGFR | P00533 | 3/20 | 0.84 |
| ▸ | PLK4 | O00444 | 2/20 | 0.84 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.84 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.84 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.84 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.84 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sunitinib SCHEMBL55459 | 1.00 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL1772213 | 1.00 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL1772212 | 1.00 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL29371243 | 1.00 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL2724453 | 0.93 | KDR (0.89) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL15264678 | 0.92 | KDR (0.93) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL25343935 | 0.92 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL20805212 | 0.92 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL25343938 | 0.92 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 | |
| Sunitinib SCHEMBL8082 | 0.92 | KDR (1.00) | KDRPDGFRBCSF1RABCB11PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016079332-A1 | GEL FORMULATIONS FOR IMPROVING IMMUNOTHERAPY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2016-05-26 | — | — | WO | claimed |
| US-20150079155-A1 | Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole Blood | BIONEER A/S (DK) | 2015-03-19 | — | — | US | claimed |
| EP-2825158-A1 | CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD | Bioneer A/S (DK) | 2015-01-21 | — | — | EP | claimed |
| WO-2014175444-A1 | ANTI-NLRR1 ANTIBODY | 千葉県 (JP) | 2014-10-30 | — | — | WO | claimed |
| WO-2013135800-A1 | CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD | BIONEER A/S (DK) | 2013-09-19 | — | — | WO | claimed |
| EP-2638896-A1 | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood | Bioneer A/S (DK) | 2013-09-18 | — | — | EP | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12421556-B2 | Materials and methods for stratifying and treating cancers | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2025-09-23 | — | — | US | disclosed |
| WO-2025124415-A1 | TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS | NIKANG THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025123318-A1 | TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2025-06-19 | — | — | WO | disclosed |
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2025-05-08 | — | — | US | disclosed |
| US-12226527-B2 | Gel formulations for local drug release | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2025-02-18 | — | — | US | disclosed |
| CN-119104658-A | Method for detecting valicarb-isopropyl tartrate genotoxic impurity D | 山东百诺医药股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20110257237-A1 | PROCESS FOR THE PREPARATION OF CRYSTALLINE FORMS OF SUNITINIB MALATE | GENERICS [UK] LIMITED (GB) | 2011-10-20 | — | — | US | disclosed |
| EP-2340248-A2 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | The Regents of the University of California (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20110112164-A1 | NOVEL POLYMORPHS AND PROCESSES FOR THEIR PREPARATION | GENERICS (UK) LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| WO-2011018090-A1 | PREDICTIVE MARKER FOR HYDROXYUREA RESISTANCE | ANDERSEN STIG UGGERHOEJ (DK) | 2011-02-17 | — | — | WO | disclosed |
| EP-2252607-A2 | NOVEL POLYMORPHS AND PROCESSES FOR THEIR PREPARATION | Generics [UK] Limited (GB) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010031056-A2 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009104021-A2 | NOVEL POLYMORPHS AND PROCESSES FOR THEIR PREPARATION | GENERICS [UK] LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257237-A1 | PROCESS FOR THE PREPARATION OF CRYSTALLINE FORMS OF SUNITINIB MALATE | SLC16A1, MDH1, GLS | KDR 13/4885PDGFRB 424/4885CSF1R 1195/4885 |
| US-20110112164-A1 | NOVEL POLYMORPHS AND PROCESSES FOR THEIR PREPARATION | FLT4, MDM4, SLC16A3 | KDR 9/4885PDGFRB 713/4885CSF1R 2588/4885 |
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TREH, GALE, SLC2A8 | KDR 2574/4885PDGFRB 4428/4885CSF1R 2899/4885 |
| US-12226527-B2 | Gel formulations for local drug release | TREH, GALE, SLC2A8 | KDR 2574/4885PDGFRB 4428/4885CSF1R 2899/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | KDR 4542/4885PDGFRB 2435/4885CSF1R 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.